Polaris Market Research Releases Targeted Protein Degradation Market Outlook 2026-2034: FDA-Approved PROTAC Drives Growth

New industry analysis projects a USD 3,531.80 Million targeted protein degradation market by 2034 as the first FDA-approved PROTAC therapy, expanding molecular glue programs, and advancing late-stage clinical pipelines reshape the next phase of precision therapeutics.

Market Size 2025	Forecast 2034	CAGR 2026-2034	Leading Region
USD 687.90 Million	USD 3,531.80 Million	19.9%	North America (50.0%)

Polaris Market Research & Consulting has released its Targeted Protein Degradation Market Report 2026-2034. The market was valued at USD 687.90 million in 2025 and is projected to reach USD 3,531.80 million by 2034, registering a CAGR of 19.9% during the forecast period. Market growth is supported by the approval of the first PROTAC therapy, increasing pharmaceutical investment in targeted protein degradation platforms, expanding molecular glue development programs, and continued progress across oncology and immunology clinical pipelines.

The recent industrial changes have added more value to the business prospects of protein degradation. In May 2026, Arvinas received approval from the FDA for their drug VEPPANU (vepdegestrant) and marked the first ever approved use of PROTACs. Later that month, Arvinas and Pfizer entered an agreement granting Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU.

“The approval of the first PROTAC therapy marks an important transition for targeted protein degradation from scientific validation to commercial execution. Organizations that combine differentiated degrader platforms with strong clinical evidence, manufacturing capabilities, commercialization expertise, and strategic partnerships are expected to strengthen their competitive position as the market continues to mature.” — Prajakta Bengale, Senior Healthcare Analyst

Targeted Protein Degradation Market Investment Signals 2026

Investment Theme	Market Signal	Business Implication
Commercialization Readiness	FDA approval of the first PROTAC therapy followed by the transfer of global commercialization rights for VEPPANU	Highlights the importance of launch capabilities, manufacturing expertise, and market access alongside platform innovation
Late-Stage Clinical Development	C4 Therapeutics initiated the registrational Phase 2 MOMENTUM study for cemsidomide	Supports investment in programs with defined regulatory pathways and late-stage clinical milestones
Combination Therapy Expansion	C4 Therapeutics advanced a Phase 1b combination study of cemsidomide with elranatamab	Reinforces opportunities for combination treatment strategies across targeted protein degradation programs
Regulatory Validation	FDA approval established the first commercial precedent for a PROTAC therapy	Strengthens confidence in companies with clinically validated degrader platforms and regulatory progress

Source: Polaris Market Research Analysis

Three Market Developments Reshaping the Targeted Protein Degradation Industry in 2026

Regulatory Approval Is Accelerating Commercial Adoption

The approval of the first PROTAC therapy has established an important commercial and regulatory benchmark for targeted protein degradation. This milestone provides greater confidence in the therapeutic approach while supporting continued investment across clinical development, manufacturing, and commercialization activities.

Clinical Pipelines Remain Active Past Early-Stage Discoveries

Protein degradation technology companies continue their progress toward clinical development in many late-stage pipelines for various disease indications within oncology and beyond. Registrational studies and combination therapy efforts increase the potential to commercialize products and provide future market opportunities.

Strategic Partnerships Enhance Value of Platforms

Pharmaceutical firms are continuously developing their target protein degradation portfolios through strategic licensing deals and clinical development alliances. The alliances are enabling faster product development and enhanced access to manufacturing expertise, regulatory capabilities, and commercialization infrastructure.

Request a free sample copy or read the full market insights : Targeted Protein Degradation Market Report

About the Polaris Targeted Protein Degradation Market Report 2026-2034

The report provides comprehensive analysis of market size, segmentation, regional trends, competitive landscape, and technology developments across the targeted protein degradation ecosystem. It is designed for pharmaceutical companies, biotechnology firms, contract research organizations, investors, academic research institutions, and healthcare stakeholders seeking strategic insights into emerging market opportunities, clinical innovation, partnership activity, and competitive positioning.

Report coverage: Market size and CAGR by technology, application, therapeutic area, and end user | Regional analysis across 5 regions with country-level breakdowns | Competitive landscape and company benchmarking | Technology and innovation assessment | Regulatory environment analysis | PDF and Excel formats | Customization available by country, region, and segment

Key Companies Profiled

Amphista Therapeutics Ltd.
Arvinas Inc.
Betta Pharmaceuticals Co. Ltd.
Bristol Myers Squibb Company
C4 Therapeutics Inc.
Cullgen Inc.
Dialectic Therapeutics Inc.
Kymera Therapeutics Inc.
Monte Rosa Therapeutics Inc.
Nurix Therapeutics Inc.
Pfizer Inc.
Relay Therapeutics Inc.

Market Segments Covered in the Targeted Protein Degradation Market Report

By Technology Outlook (Revenue, USD Billion, 2021–2034)

PROTACs (Heterobifunctional Degraders)
Molecular Glues
LYTACs (Lysosome-Targeting Chimeras)
Degrader-Antibody Conjugates
Other Induced-Proximity Modalities

By Application Outlook (Revenue, USD Billion, 2021–2034)

Therapy Development
Target Identification and Validation
Drug Discovery Research Tools
Others

By Therapeutic Area Outlook (Revenue, USD Billion, 2021–2034)

Oncology
Immunology and Inflammation
Neurology and Neurodegenerative Diseases
Infectious Diseases
Others

By End User Outlook (Revenue, USD Billion, 2021–2034)

Pharmaceutical and Biotechnology Companies
Contract Research Organizations (CROs) and Specialist Providers
Academic and Research Institutions
Others

By Regional Outlook (Revenue, USD Billion, 2021–2034)

North America

US
Canada

Europe

Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe

Asia Pacific

China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific

Middle East & Africa

Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa

Latin America

Mexico
Brazil
Argentina
Rest of Latin America